文献速递核素与放射性配体治疗肿瘤 PET/CT

177Lu-PSMA延长治疗转移性去势抵抗性前列腺癌

177Lu-PSMA for Extended Treatment of Metastatic Castration-Resistant Prostate Cancer.
PubMed 文献 · J Nucl Med · 2022-07-19

研究评估了转移性去势抵抗性前列腺癌(mCRPC)患者延长177Lu-PSMA放射性配体治疗(RLT)的可行性、额外获益与毒性。208例接受177Lu-PSMA治疗的患者中,26例在6周期后未进展且未出现≥3级毒性者继续治疗至疾病进展、完全缓解、因毒性或患者意愿退出。延长治疗(最多13周期)期间50%患者获得额外PSA下降(-52%±34%,范围1%至100%),8%患者获得PSA与影像学一致的完全缓解,中位PFS为450天。急性毒性包括骨髓抑制均为轻度(≤2级),口干和慢性肾病随重复给药更常见。结论认为延长177Lu-PSMA治疗在mCRPC中可行且有效。

要点

  • 6周期后未进展且无≥3级毒性者延长177Lu-PSMA治疗可行。
  • 延长治疗期间50%患者PSA额外下降-52%±34%,8%达完全缓解。
  • 急性毒性≤2级,口干和慢性肾病随重复给药更常见。

核心结论

  • 延长177Lu-PSMA治疗在转移性去势抵抗性前列腺癌中可行且有效。

研究设计与样本

  • 从208例每6-8周接受177Lu-PSMA治疗的患者中,纳入26例6周期后未进展且未出现≥3级毒性并继续治疗者。
  • 继续治疗至疾病进展、完全缓解、因毒性或患者意愿退出,评估缓解率、额外获益与毒性。

主要发现

  • 延长治疗(最多13周期)期间50%患者获得额外PSA下降(-52%±34%,范围1%至100%)。
  • 8%患者获得PSA与影像学一致的完全缓解。
  • 中位PFS为450天。
  • 急性毒性包括骨髓抑制均为轻度(≤2级)。
  • 口干和慢性肾病随重复给药更常见。

临床怎么用

  • 原文结论认为延长177Lu-PSMA治疗在mCRPC中可行且有效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To evaluate feasibility, additional benefit and toxicity of treatment extension of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC). Methods: From 208 patients treated with 177Lu-PSMA every 6-8 weeks, 26 patients who had not progressed and not experienced ≥grade 3 toxicity after 6 cycles continued to receive 177Lu-PSMA until disease progression or complete remission or removal from treatment for toxicity or patient preference. Response rates, the additional benefit of treatment extension, and toxicity were assessed. Results: During treatment extension (up to 13 cycles), 50% of patients achieved an additional PSA decline (-52%±34%, range 1% to 100%), with 8% of patients receiving congruent PSA-based and imaging-based complete response. Median PFS was 450 days. Acute toxicity, including myelosuppression, was mild (≤ grade 2). Xerostomia and chronic kidney disease became more common with repetitive dosing. Conclusion: Extension of 177Lu-PSMA treatment is feasible and effective in mCRPC.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Derlin T, Widjaja L, Werner RA, et al. 177Lu-PSMA for Extended Treatment of Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2022. PMID: 35853739. doi:10.2967/jnumed.122.264293

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。